多西紫杉醇联合表柔比星新辅助化疗治疗乳腺癌的疗效分析  

Effect analysis of neoadjuvant chemotherapy of docetaxel combining with pharmorubicin in the treatment of breast cancer

作　　者：刘亮[1] 张森[1] 

机构地区：[1]山东省警官总医院外科,济南250002

出　　处：《中国肿瘤临床与康复》2014年第6期703-705,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨多西紫杉醇联合表柔比星(ET方案)在乳腺癌新辅助化疗应用中的临床效果。方法选取70例原发性乳腺癌患者作为研究对象,所有患者均采用ET方案进行新辅助化疗,治疗4个疗程后,分析治疗效果和不良反应的发生情况。结果 ET方案新辅助化疗治疗乳腺癌的有效率为75.8%,治疗后患者发生不同程度的呕吐、粒细胞减少和脱发等不良反应。结论对乳腺癌患者行多西紫杉醇联合表柔比星新辅助化疗能够有效提高肿瘤治疗的有效率,不良反应患者可耐受,ET方案是新辅助化疗治疗乳腺癌较为理想的选择。Objective To explore the effect of neoadjuvant chemotherapy of docetaxel combining with pharmorubicin in the treatment of breast cancer. Methods Seventy patients with primary breast cancer were enrolled into this study, all patients were treated with neoadjuvant chemotherapy of docetaxel and phar- morubicin. After four cycles of treatment, the effects and adverse reaction were observed and analyzed. Conclusion The effective rate of neoadjuvant chemotherapy of docetaxel combining with pharmorubicin in the treatment of breast cancer was 75. 8%. Patients had different degree of adverse reaction, such as vomi- ting, granuloeytopenia and hair loss. Conclusion Neoadjuvant chemotherapy of docetaxel combining with pharmorubicinfor for the treatment of breast cancer can improve the efficient rate of tumor treatment, patents could tolerate the adverse reaction, The scheme of neoadjuvant chemotherapy is ideal choice for the treatment of breast cancer.

关 键 词：乳腺肿瘤 多西紫杉醇 表柔比星 新辅助化疗 治疗结果 

分 类 号：R737.9[医药卫生—肿瘤]